IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

IDEAYA Biosciences (NASDAQ: IDYA) announced on November 28, 2025 that its Compensation Committee granted non-qualified stock options on November 26, 2025 to a newly hired employee under the 2023 Inducement Plan pursuant to Nasdaq Listing Rule 5635(c)(4).

The grant totals 17,600 options with an exercise price of $35.88 per share (equal to the closing Nasdaq price on the grant date). Options carry a 10-year term and vest over four years: 25% on the first anniversary of the vesting commencement date and the remaining 75% in equal monthly installments over the following three years, subject to continued service.

News Market Reaction

-0.72%

1 alert

-0.72% News Effect

On the day this news was published, IDYA declined 0.72%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Inducement options: 17,600 options Exercise price: $35.88 per share Option term: 10-year term +2 more

5 metrics

Inducement options 17,600 options Grant to newly hired employee under 2023 Inducement Plan

Exercise price $35.88 per share Equal to Nasdaq closing price on Nov 26, 2025 grant date

Option term 10-year term Non-qualified stock options granted under inducement plan

Initial vesting 25% at 1 year First anniversary of vesting commencement date

Remaining vesting 75% over 3 years Equal monthly installments after first anniversary

Market Reality Check

Price: $36.20 Vol: Volume 585,285 versus 20-...

low vol

$36.20 Last Close

Volume Volume 585,285 versus 20-day average 947,163 indicates lighter-than-normal trading ahead of this routine HR announcement. low

Technical Shares at $33.56 are trading above the 200-day moving average of $23.72 and sit 9.49% below the 52-week high of $37.08.

Peers on Argus

Among close biotechnology peers, only DNLI appeared in the momentum scanner, mov...

1 Up

Among close biotechnology peers, only DNLI appeared in the momentum scanner, moving up 5.35% without same-day news. Other listed peers showed modest moves, suggesting today’s setup around IDYA is stock-specific rather than a coordinated sector move.

Historical Context

5 past events · Latest: Dec 10 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Dec 10	IND submission	Positive	-1.3%	Filed IND for IDE574 targeting Phase 1 monotherapy trial in Q1 2026.
Dec 04	IND clearance	Positive	+4.7%	FDA IND clearance for IDE034 bispecific ADC with Phase 1 enrollment in Q1 2026.
Dec 01	IND clearance	Positive	-3.7%	Announced FDA IND clearance for IDE034 enabling Phase 1 trial in solid tumors.
Nov 28	Equity compensation	Neutral	-0.7%	Granted 17,600 stock options to a new hire under 2023 Inducement Plan.
Nov 24	Investor events	Neutral	+2.0%	Announced CEO participation in early December 2025 healthcare conferences.

Pattern Detected

Recent IDYA news has shown mixed price reactions: positive clinical and regulatory updates sometimes sold off, while other clearances and corporate updates saw gains, indicating inconsistent alignment between news tone and short-term trading.

Recent Company History

Over the last few weeks, IDEAYA reported several pipeline and corporate milestones. On Nov 24, 2025, it outlined upcoming investor events, followed by inducement stock option grants on Nov 28, 2025 totaling 17,600 options at $35.88 per share. Early December brought FDA IND clearance for IDE034 and then an IND submission for IDE574, with multiple Phase 1 trials targeted for Q1 2026. Price reactions to these otherwise constructive updates have alternated between gains and pullbacks, underscoring variable short-term sentiment.

Market Pulse Summary

This announcement details a standard inducement equity grant: 17,600 non-qualified stock options at ...

Analysis

This announcement details a standard inducement equity grant: 17,600 non-qualified stock options at an exercise price of $35.88 per share, with a 10-year term and four-year vesting schedule. It ties to Nasdaq Listing Rule 5635(c)(4) and is limited to a single new hire under the 2023 Inducement Plan. Investors may monitor future grants, overall share-based compensation levels, and subsequent clinical or regulatory updates for more material catalysts.

Key Terms

non-qualified stock options, Nasdaq Listing Rule 5635(c)(4)

2 terms

non-qualified stock options financial

"granted non-qualified stock options to purchase an aggregate of 17,600 shares"

Non-qualified stock options are a type of employee benefit that gives individuals the right to buy company shares at a set price, usually lower than the market value, within a certain period. Unlike other options that may have special tax advantages, these options are taxed as income when exercised, which can affect how much money the employee or investor ultimately gains. They are important because they can influence company compensation strategies and impact the financial outcomes for employees and investors.

Nasdaq Listing Rule 5635(c)(4) regulatory

"as an inducement material to such individual entering into employment with IDEAYA in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

AI-generated analysis. Not financial advice.

SOUTH SAN FRANCISCO, Calif., Nov. 28, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on November 26, 2025, the Compensation Committee of IDEAYA's Board of Directors granted non-qualified stock options to purchase an aggregate of 17,600 shares of the Company's common stock to a newly hired employee. The stock options were granted under the IDEAYA Biosciences, Inc. 2023 Employment Inducement Incentive Award Plan (2023 Inducement Plan) as an inducement material to such individual entering into employment with IDEAYA in accordance with Nasdaq Listing Rule 5635(c)(4).

The 2023 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of IDEAYA, or following a bona fide period of non-employment, as an inducement material to such individuals' entering into employment with IDEAYA, pursuant to Nasdaq Listing Rule 5635(c)(4).

The stock options have an exercise price of $35.88 per share, which is equal to the closing price of IDEAYA's common stock on The Nasdaq Global Select Market on the date of grant. The stock options have a 10-year term and will vest over four years, with 25% of the options vesting on the first anniversary of the vesting commencement date and the remaining 75% of the options vesting in equal monthly installments over the three years thereafter. Vesting of the stock options is subject to such employee's continued service to IDEAYA on each vesting date.

About IDEAYA Biosciences

IDEAYA is a precision medicine oncology company committed to the discovery, development, and commercialization of transformative therapies for cancer.  Our approach integrates expertise in small-molecule drug discovery, structural biology and bioinformatics with robust internal capabilities in identifying and validating translational biomarkers to develop tailored, potentially first-in-class targeted therapies aligned to the genetic drivers of disease.  We have built a deep pipeline of product candidates focused on synthetic lethality and antibody-drug conjugates, or ADCs, for molecularly defined solid tumor indications.  Our mission is to bring forth the next wave of precision oncology therapies that are more selective, more effective, and deeply personalized with the goal of altering the course of disease and improving clinical outcomes for patients with cancer.

Investor and Media Contact
IDEAYA Biosciences
Joshua Bleharski, Ph.D.
Chief Financial Officer 
investor@ideayabio.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/ideaya-biosciences-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-302627243.html

SOURCE IDEAYA Biosciences, Inc.

FAQ

What did IDEAYA (IDYA) announce on November 28, 2025 regarding employee stock options?

IDEAYA announced a grant of 17,600 non-qualified stock options to a newly hired employee, approved November 26, 2025, under the 2023 Inducement Plan.

What is the exercise price and term of the IDYA inducement stock options granted November 26, 2025?

The options have an exercise price of $35.88 per share and a 10-year term.

How do the IDYA inducement options vest and when does vesting begin?

Vesting is over four years: 25% vests on the first anniversary of the vesting commencement date, then the remaining 75% vests in equal monthly installments over the next three years, subject to continued service.

Under what plan and Nasdaq rule were the IDEAYA (IDYA) inducement grants made?

The grant was made under the 2023 Inducement Plan as an inducement material to employment in accordance with Nasdaq Listing Rule 5635(c)(4).

Does the $35.88 exercise price reflect IDEAYA's market price on the grant date?

Yes. The exercise price of $35.88 equals IDEAYA's closing price on The Nasdaq Global Select Market on the date of grant.